Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2020 (Filed February 7, 2020)
Principal Executive Offices: Dublin, Ireland
This filing serves as a notification of changes in substantial holdings and does not contain a full financial report for the period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding ownership changes rather than a financial results report.
Material Changes
The primary material change disclosed in this filing is the submission of two exhibits detailing a "Change in Substantial Holding" (Exhibits 99.1 and 99.2). No operational or financial changes are detailed in the body of this specific text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes an extensive disclaimer regarding forward-looking statements. These statements cover future performance, capital expenditure, credit facilities, dividends, and tax structures.
Key Risks Identified:
- Liabilities related to prior asbestos product manufacture and contributions to the Asbestos Injuries Compensation Fund (AICF).
- Currency exchange rate fluctuations affecting financial statements.
- Changes in tax laws and treatments.
- Competition, product pricing, and potential product failures.
- Legal proceedings, including environmental and consumer class actions.
- General economic conditions, housing market recovery, and interest rates.
- Integration of Fermacell into the business.
Investor Verification Checklist
- Review Exhibits 99.1 and 99.2 (not included in this text) to identify the specific parties involved in the change of substantial holding.
- Consult the most recent Form 20-F or quarterly earnings release for actual financial performance metrics (revenue, profit, cash flow).
- Monitor updates regarding the Asbestos Injuries Compensation Fund (AICF) contribution requirements and potential shortfalls.
- Verify the status of the Fermacell integration and associated capital expenditure projects.